Related Experiment Video
Updated: Aug 7, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Losartan-Associated Sub-fulminant Hepatitis: A Case Report
Kanwarpreet Sadhu1, Rakshand Shetty2, Prachi Mehmi3
1Medicine, All India Institute of Medical Sciences, Bathinda, IND.
Losartan, an angiotensin II receptor blocker, can rarely cause severe drug-induced liver injury (DILI) and acute liver failure. Early recognition is crucial for managing this rare but potentially fatal adverse effect.
Area of Science:
- Hepatology
- Pharmacology
- Internal Medicine
Background:
- Losartan is a widely used angiotensin II receptor blocker for hypertension.
- Drug-induced liver injury (DILI) from losartan is a rare but serious adverse effect.
- Acute liver failure (ALF) can occur in severe cases of losartan-induced hepatotoxicity.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Potassium-Sparing Diuretics
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
